Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome
Quoin $QNRX receives FDA Fast Track Designation for QRX003 in Peeling Skin Syndrome, with a Phase 2/3 study expected to begin in 2H 2026.